An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials

Yufen Huang, Wan Jung Chang, Chin Fu Hsiao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To accelerate the drug development process and shorten approval time, the design of multiregional clinical trials (MRCTs) incorporates subjects from many countries/regions around the world under the same protocol. After showing the overall efficacy of a drug in all global regions, one can also simultaneously evaluate the possibility of applying the overall trial results to all regions and subsequently support drug registration in each of them. In this paper, we focus on a specific region and establish a statistical criterion to assess the consistency between the specific region and overall results in an MRCT. More specifically, we treat each region in an MRCT as an independent clinical trial, and each perhaps has different treatment effect. We then construct the empirical prior information for the treatment effect for the specific region on the basis of all of the observed data from other regions. We will conclude similarity between the specific region and all regions if the posterior probability of deriving a positive treatment effect in the specific region is large, say 80%. Numerical examples illustrate applications of the proposed approach in different scenarios.

Original languageEnglish
Pages (from-to)59-64
Number of pages6
JournalPharmaceutical Statistics
Volume12
Issue number2
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

Empirical Bayes
Clinical Trials
Evaluation
Pharmaceutical Preparations
Treatment Effects
Drugs
Posterior Probability
Prior Information
Development Process
Registration
Accelerate
Efficacy

All Science Journal Classification (ASJC) codes

  • Statistics and Probability
  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{ef4741bca54f434890be0574941b7c42,
title = "An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials",
abstract = "To accelerate the drug development process and shorten approval time, the design of multiregional clinical trials (MRCTs) incorporates subjects from many countries/regions around the world under the same protocol. After showing the overall efficacy of a drug in all global regions, one can also simultaneously evaluate the possibility of applying the overall trial results to all regions and subsequently support drug registration in each of them. In this paper, we focus on a specific region and establish a statistical criterion to assess the consistency between the specific region and overall results in an MRCT. More specifically, we treat each region in an MRCT as an independent clinical trial, and each perhaps has different treatment effect. We then construct the empirical prior information for the treatment effect for the specific region on the basis of all of the observed data from other regions. We will conclude similarity between the specific region and all regions if the posterior probability of deriving a positive treatment effect in the specific region is large, say 80{\%}. Numerical examples illustrate applications of the proposed approach in different scenarios.",
author = "Yufen Huang and Chang, {Wan Jung} and Hsiao, {Chin Fu}",
year = "2013",
month = "3",
day = "1",
doi = "10.1002/pst.1553",
language = "English",
volume = "12",
pages = "59--64",
journal = "Pharmaceutical Statistics",
issn = "1539-1604",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials. / Huang, Yufen; Chang, Wan Jung; Hsiao, Chin Fu.

In: Pharmaceutical Statistics, Vol. 12, No. 2, 01.03.2013, p. 59-64.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials

AU - Huang, Yufen

AU - Chang, Wan Jung

AU - Hsiao, Chin Fu

PY - 2013/3/1

Y1 - 2013/3/1

N2 - To accelerate the drug development process and shorten approval time, the design of multiregional clinical trials (MRCTs) incorporates subjects from many countries/regions around the world under the same protocol. After showing the overall efficacy of a drug in all global regions, one can also simultaneously evaluate the possibility of applying the overall trial results to all regions and subsequently support drug registration in each of them. In this paper, we focus on a specific region and establish a statistical criterion to assess the consistency between the specific region and overall results in an MRCT. More specifically, we treat each region in an MRCT as an independent clinical trial, and each perhaps has different treatment effect. We then construct the empirical prior information for the treatment effect for the specific region on the basis of all of the observed data from other regions. We will conclude similarity between the specific region and all regions if the posterior probability of deriving a positive treatment effect in the specific region is large, say 80%. Numerical examples illustrate applications of the proposed approach in different scenarios.

AB - To accelerate the drug development process and shorten approval time, the design of multiregional clinical trials (MRCTs) incorporates subjects from many countries/regions around the world under the same protocol. After showing the overall efficacy of a drug in all global regions, one can also simultaneously evaluate the possibility of applying the overall trial results to all regions and subsequently support drug registration in each of them. In this paper, we focus on a specific region and establish a statistical criterion to assess the consistency between the specific region and overall results in an MRCT. More specifically, we treat each region in an MRCT as an independent clinical trial, and each perhaps has different treatment effect. We then construct the empirical prior information for the treatment effect for the specific region on the basis of all of the observed data from other regions. We will conclude similarity between the specific region and all regions if the posterior probability of deriving a positive treatment effect in the specific region is large, say 80%. Numerical examples illustrate applications of the proposed approach in different scenarios.

UR - http://www.scopus.com/inward/record.url?scp=84874978531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874978531&partnerID=8YFLogxK

U2 - 10.1002/pst.1553

DO - 10.1002/pst.1553

M3 - Article

C2 - 23319408

AN - SCOPUS:84874978531

VL - 12

SP - 59

EP - 64

JO - Pharmaceutical Statistics

JF - Pharmaceutical Statistics

SN - 1539-1604

IS - 2

ER -